NTRA vs. LH, DGX, EXAS, RDNT, GH, FTRE, VCYT, CDNA, VRDN, and CSTL
Should you be buying Natera stock or one of its competitors? The main competitors of Natera include Laboratory Co. of America (LH), Quest Diagnostics (DGX), Exact Sciences (EXAS), RadNet (RDNT), Guardant Health (GH), Fortrea (FTRE), Veracyte (VCYT), CareDx (CDNA), Viridian Therapeutics (VRDN), and Castle Biosciences (CSTL). These companies are all part of the "medical laboratories" industry.
Laboratory Co. of America (NYSE:LH) and Natera (NASDAQ:NTRA) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, community ranking, analyst recommendations, dividends, media sentiment, institutional ownership and profitability.
Laboratory Co. of America has higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than Laboratory Co. of America, indicating that it is currently the more affordable of the two stocks.
Laboratory Co. of America received 144 more outperform votes than Natera when rated by MarketBeat users. However, 68.52% of users gave Natera an outperform vote while only 64.14% of users gave Laboratory Co. of America an outperform vote.
95.9% of Laboratory Co. of America shares are held by institutional investors. Comparatively, 99.9% of Natera shares are held by institutional investors. 0.9% of Laboratory Co. of America shares are held by company insiders. Comparatively, 7.6% of Natera shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Laboratory Co. of America has a beta of 1.02, indicating that its share price is 2% more volatile than the S&P 500. Comparatively, Natera has a beta of 1.38, indicating that its share price is 38% more volatile than the S&P 500.
Laboratory Co. of America has a net margin of 3.52% compared to Laboratory Co. of America's net margin of -30.24%. Natera's return on equity of 14.68% beat Laboratory Co. of America's return on equity.
Laboratory Co. of America currently has a consensus target price of $243.14, suggesting a potential upside of 22.66%. Natera has a consensus target price of $98.47, suggesting a potential downside of 10.54%. Given Natera's higher probable upside, equities analysts clearly believe Laboratory Co. of America is more favorable than Natera.
In the previous week, Natera had 9 more articles in the media than Laboratory Co. of America. MarketBeat recorded 16 mentions for Natera and 7 mentions for Laboratory Co. of America. Natera's average media sentiment score of 1.58 beat Laboratory Co. of America's score of 0.83 indicating that Laboratory Co. of America is being referred to more favorably in the media.
Summary
Laboratory Co. of America beats Natera on 10 of the 18 factors compared between the two stocks.
Get Natera News Delivered to You Automatically
Sign up to receive the latest news and ratings for NTRA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NTRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
